Dean C. Pavlick
YOU?
Author Swipe
View article: Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study
Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study Open
View article: Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma
Low PD-L1 expression, MAP2K2 alterations, and enriched HPV gene signatures characterize brain metastases in head and neck squamous cell carcinoma Open
HNSCC patients with BM frequently have oropharyngeal primary sites and are HPV+. Common molecular alterations in BM samples, including targetable PIK3CA and ATM, were identified. MAP2K2 alterations were enriched and densities of immune cel…
View article: Molecular characteristics of advanced colorectal cancer and multi-hit <i>PIK3CA</i> mutations
Molecular characteristics of advanced colorectal cancer and multi-hit <i>PIK3CA</i> mutations Open
Introduction Approximately 20% of patients living with colorectal cancer (CRC) have activating mutations in their tumors in the PIK3CA oncogene. Two or more activating mutations (multi-hit) for the PIK3CA allele increase PI3K⍺ signaling co…
View article: Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study
Single-Hit and Multi-hit PIK3CA Short Variant Genomic Alterations in Clinically Advanced Prostate Cancer: A Genomic Landscape Study Open
View article: Age and Sex Affects the Frequency and Mutation Type of <i>FGFR2</i> Alterations in Cholangiocarcinoma
Age and Sex Affects the Frequency and Mutation Type of <i>FGFR2</i> Alterations in Cholangiocarcinoma Open
PURPOSE FGFR2 alterations are infrequent but currently represent the most common targetable mutation in cholangiocarcinoma. We performed a large-scale genomic analysis to assess associations between FGFR2 and other driver gene alterations …
View article: Understanding variants of unknown significance and classification of genomic alterations
Understanding variants of unknown significance and classification of genomic alterations Open
Despite recent efforts to issue clinical guidelines outlining strategies to define the pathogenicity of genomic variants, there is currently no standardized framework for which to make these assertions. This review does not present a step-…
View article: 439 Extracellular-in-frame deletions and kinase domain duplications are novel, gain-of-function mutations in fibroblast growth factor receptor genes in cancer
439 Extracellular-in-frame deletions and kinase domain duplications are novel, gain-of-function mutations in fibroblast growth factor receptor genes in cancer Open
OBJECTIVES/GOALS: There are gain-of-function genomic alterations in FGFR genes that guide personalized treatment in some patients with cholangiocarcinoma (10%) and bladder cancer (30%) who can benefit from targeted therapies. We sought to …
View article: Supplementary Data 2 from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Supplementary Data 2 from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types Open
Supplementary Tables
View article: Supplementary Data 2 from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Supplementary Data 2 from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types Open
Supplementary Tables
View article: Data from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Data from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types Open
Purpose:Genomic rearrangements can generate potent oncogenic drivers or disrupt tumor suppressor genes. This study examines the landscape of fusions and rearrangements detected by liquid biopsy (LBx) of circulating tumor DNA (ctDNA) across…
View article: Supplementary Data 1 from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Supplementary Data 1 from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types Open
Supplementary Figures
View article: Data from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Data from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types Open
Purpose:Genomic rearrangements can generate potent oncogenic drivers or disrupt tumor suppressor genes. This study examines the landscape of fusions and rearrangements detected by liquid biopsy (LBx) of circulating tumor DNA (ctDNA) across…
View article: Supplementary Data 1 from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Supplementary Data 1 from Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types Open
Supplementary Figures
View article: Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers Open
Background One of the most common sporadic homozygous deletions in cancers is 9p21 loss, which includes the genes methylthioadenosine phosphorylase (MTAP), CDKN2A, and CDKN2B, and has been correlated with worsened outcomes and immunotherap…
View article: Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden
Genomic Profiles and Clinical Outcomes of Penile Squamous Cell Carcinoma With Elevated Tumor Mutational Burden Open
Importance Tumor mutational burden (TMB) is a putative biomarker of efficacy for immune checkpoint inhibitor (ICI) therapies of solid tumors, but not specifically for penile squamous cell carcinoma (PSCC). Objective To characterize biomark…
View article: Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types
Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types Open
Purpose: Genomic rearrangements can generate potent oncogenic drivers or disrupt tumor suppressor genes. This study examines the landscape of fusions and rearrangements detected by liquid biopsy (LBx) of circulating tumor DNA (ctDNA) acros…
View article: Data from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Data from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Purpose:BRAF mutations are rare in biliary tract cancers (BTC), but are of interest given the recent developments in targeted therapy for BTC. We investigated the clinical outcomes in a cohort of BRAF-mutant advanced BTC trea…
View article: Supplementary Figure S1 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Figure S1 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Figure S1: Progression Free Survival separated out by individual mutation classes
View article: Supplementary Figure S1 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Figure S1 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Figure S1: Progression Free Survival separated out by individual mutation classes
View article: Supplementary Table S4 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S4 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S4: OS Cox Regression with Univariate, Full Multivariate, and Explanatory Multivariate Analysis
View article: Supplementary Figure S2 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Figure S2 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Figure S2: Overall Survival separated out by individual mutation classes.
View article: Supplementary Table S5 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S5 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S5: Early Phase Clinical Trials of BRAF Dimer Inhibitors or Breakers
View article: Supplementary Table S3 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S3 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S3: PFS Cox Regression with Univariate, Full Multivariate, and Explanatory Multivariate Analysis
View article: Supplementary Table S3 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S3 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S3: PFS Cox Regression with Univariate, Full Multivariate, and Explanatory Multivariate Analysis
View article: Supplementary Table S2 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S2 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S2: Categorical Variables Used for the Comparative Genomics Analyses
View article: Supplementary Table S2 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S2 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S2: Categorical Variables Used for the Comparative Genomics Analyses
View article: Data from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Data from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Purpose:BRAF mutations are rare in biliary tract cancers (BTC), but are of interest given the recent developments in targeted therapy for BTC. We investigated the clinical outcomes in a cohort of BRAF-mutant advanced BTC trea…
View article: Supplementary Table S4 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S4 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S4: OS Cox Regression with Univariate, Full Multivariate, and Explanatory Multivariate Analysis
View article: Supplementary Table S5 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S5 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S5: Early Phase Clinical Trials of BRAF Dimer Inhibitors or Breakers
View article: Supplementary Table S1 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers
Supplementary Table S1 from Comparative Genomic Analysis and Clinical Outcomes of <i>BRAF</i>-mutated Advanced Biliary Tract Cancers Open
Supplemental Table S1: Extended data on the clinicodemographics for the Genomics Cohort